Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
NysnoBio GT Neurology, LLC maintains a portfolio in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently active. This 1 pending office action is assigned to 1 distinct examiner and is located within 1 distinct art unit. JOSEPHINE MARIA GONZALES is the busiest examiner for the portfolio, overseeing 1 pending office action. As there is only 1 pending office action total, this examiner is responsible for the entirety of the company's current pending prosecution.
The focus on 1 distinct examiner and 1 distinct art unit for the 1 pending office action suggests a specialized patenting effort within the Biotechnology & Pharmaceuticals field. For practitioners, this concentration indicates that the progress of the company's intellectual property is dependent on the review of JOSEPHINE MARIA GONZALES. This singular point of contact within the USPTO means that the outcome of the 1 pending office action will define the company's current patent success. The nature of the 1 distinct art unit further emphasizes the technical scope of the filing.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALES, JOSEPHINE MARIA | 1 | 26.6% | +38.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18901912 | GENE THERAPY DELIVERY OF PARKIN MUTANTS HAVING INCREASED ACTIVITY TO TREAT PARKINSON'S DISEASE | GONZALES, JOSEPHINE MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18901912 | GENE THERAPY DELIVERY OF PARKIN MUTANTS HAVING INCREASED ACTIVITY TO TREAT PARKINSON'S DISEASE | GONZALES, JOSEPHINE MARIA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18901912 | GENE THERAPY DELIVERY OF PARKIN MUTANTS HAVING INCREASED ACTIVITY TO TREAT PARKINSON'S DISEASE | GONZALES, JOSEPHINE MARIA | 1631 | §102§103DP | Non-Final OA | — | Pending | Sep 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial